This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kanayama, H.-o. Articles by Ichihara, A. Search for Related Content PubMed PubMed Citation Articles by Kanayama, H.-o. Articles by Ichihara, A.

Changes in Expressions of Proteasome and Ubiquitin Genes in Human Renal Cancer Cells¹

Department of Urology, School of Medicine [H. K., M. A., S. K.] and Institute for Enzyme Research [K. T., A. I.], The University of Tokushima, Tokushima 770; Kyowa Hakko Kogyo Co., Ltd., Machida-Shi 194 [H. M., M. S., F. O., S. S.]; and Biomaterial Research Institute, Yokohama 244 [N. S.], Japan

Proteasomes and ubiquitin (Ub) are essential components of the energy- dependent, nonlysosomal proteolytic pathway. To clarify the physiological role of this proteasome/Ub-dependent pathway, we measured the levels of expressions of proteasomes and Ub in human renal cancers by Northern blot and immunochemical analyses. The mRNAs for two of the multiple subunits of proteasomes, C2 and C9, were expressed at abnormally high levels in most neoplastic lesions of patients with various primary renal cell carcinomas and in all renal cancer cell lines examined. However, no significant difference was found by enzyme immunoassay in the proteasomal contents of cancerous and normal parts of the kidney. The levels of mRNAs for the subunits of proteasomes were high in rapidly proliferating renal cells and appeared to be correlated with the activities of these cells for proteasome synthesis, but the cellular contents of proteasomes in these cells were normal, suggesting rapid turnover of proteasomes in rapidly proliferating cancer cells. Consistent with the increased expressions of proteasomal mRNAs, the expressions of three Ub genes, mono-UbA₈₀, mono-UbA₅₂, and poly-UbC, were found to be greatly increased in these renal cancer cells. Immunohistochemical staining of normal kidney showed that the levels of both proteasomes and Ub were high in cells of renal tubules and collecting ducts, but low in the glomerulus. The levels of both proteins appeared to be considerably increased in the nuclei of granular and clear carcinoma cells of the kidney. Moreover, the profiles of cellular proteins conjugated with Ub in normal kidney tissues were different from those in cancerous parts of the kidney and in established renal cancer cells. These results suggest that the proteasome- and ubiquitin-mediated system is functionally involved in the cancerous state in human kidney.

¹ This work was supported in part by a Grant-in-Aid from the Ministry of Education, Science and Culture of Japan.

² To whom correspondence should be addressed.

Received 3/ 1/91. Accepted 10/ 7/91.

This article has been cited by other articles:

				C. Jakob, K. Egerer, P. Liebisch, S. Turkmen, I. Zavrski, U. Kuckelkorn, U. Heider, M. Kaiser, C. Fleissner, J. Sterz, et al. Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma Blood, March 1, 2007; 109(5): 2100 - 2105. [Abstract] [Full Text] [PDF]

				J. Codony-Servat, M. A. Tapia, M. Bosch, C. Oliva, J. Domingo-Domenech, B. Mellado, M. Rolfe, J. S. Ross, P. Gascon, A. Rovira, et al. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol. Cancer Ther., March 1, 2006; 5(3): 665 - 675. [Abstract] [Full Text] [PDF]

				F. Diomedi-Camassei, L. Rava, E. Lerut, F. Callea, and B. Van Damme Protein gene product 9.5 and ubiquitin are expressed in metabolically active epithelial cells of normal and pathologic human kidney Nephrol. Dial. Transplant., December 1, 2005; 20(12): 2714 - 2719. [Abstract] [Full Text] [PDF]

				X. Hong, L. Lei, and R. Glas Tumors Acquire Inhibitor of Apoptosis Protein (IAP)-mediated Apoptosis Resistance through Altered Specificity of Cytosolic Proteolysis J. Exp. Med., June 16, 2003; 197(12): 1731 - 1743. [Abstract] [Full Text] [PDF]

				T. Okamura, S.-i. Taniguchi, T. Ohkura, A. Yoshida, H. Shimizu, M. Sakai, H. Maeta, H. Fukui, Y. Ueta, I. Hisatome, et al. Abnormally High Expression of Proteasome Activator-{gamma} in Thyroid Neoplasm J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1374 - 1383. [Abstract] [Full Text] [PDF]

				P. Sutovsky, R. M. Turner, S. Hameed, and M. Sutovsky Differential Ubiquitination of Stallion Sperm Proteins: Possible Implications for Infertility and Reproductive Seasonality Biol Reprod, February 1, 2003; 68(2): 688 - 698. [Abstract] [Full Text] [PDF]

				K.-i. Kiyomiya, S. Matsuo, and M. Kurebe Mechanism of Specific Nuclear Transport of Adriamycin: The Mode of Nuclear Translocation of Adriamycin-Proteasome Complex Cancer Res., March 1, 2001; 61(6): 2467 - 2471. [Abstract] [Full Text]

				P. Masdehors, H. Merle-Beral, K. Maloum, S. Omura, H. Magdelenat, and J. Delic Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes Blood, July 1, 2000; 96(1): 269 - 274. [Abstract] [Full Text] [PDF]

				E. S. Lightcap, T. A. McCormack, C. S. Pien, V. Chau, J. Adams, and P. J. Elliott Proteasome Inhibition Measurements: Clinical Application Clin. Chem., May 1, 2000; 46(5): 673 - 683. [Abstract] [Full Text] [PDF]